Pulnovo Medical Secures Tens of Millions in USD in New Funding Round Led by EQT and Qiming Venture Partners to Accelerate Global Expansion
Pulnovo Medical
Developer of Medical Devices in the Field of Pulmonary Hypertension Treatment
Qiming Venture Partners
Healthcare Investment Institutions
EQT Ventures
Venture Capital Fund
This round of financing not only affirms Pulnovo Medical’s long-term strategic trajectory but also highlights the increasing scarcity and verifiability of China-originated platforms against the backdrop of global healthcare industry cycle volatility. The funds raised in this round will be primarily allocated to expanding and advancing Pulnovo Medical’s presence in overseas markets, with key focuses including global clinical registration, expansion of product indications, and deepening of its industrialization system.
Pulnovo Medical Executive Director and CEOLian Jia stated:Over the past few years, we have laid a solid foundation step by step. Today’s recognition serves as both encouragement and responsibility. Moving forward, Pulnovo Medical will continue to adhere to a results-oriented approach, steadily advancing product commercialization and global expansion, thereby enabling truly valuable Chinese original technologies to make an impact in broader markets.
From Guidelines to Regulation: Chinese Original Technologies Forge a Global Path
Since its founding in 2013, Pulnovo Medical has been committed to global innovation, establishing a closed-loop global ecosystem encompassing “R&D, clinical application, and market commercialization.” Its proprietary core technology, Percutaneous Pulmonary Artery Denervation (PADN), has been incorporated multiple times into authoritative domestic and international guidelines and has successfully obtained EU CE-MDR certification. In 2023, it received Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA) and marketing approval from the National Medical Products Administration (NMPA). In March 2025, the second-generation PHD360 radiofrequency ablation system was also officially approved for marketing by the NMPA. Currently, Pulnovo Medical is advancing multiple global multicenter clinical trial programs: large-scale pivotal registries and international multicenter studies targeting chronic heart failure combined with Group 2 pulmonary hypertension are nearing completion in China and Europe; meanwhile, two FDA-regulated global multicenter clinical studies focusing on Group 1 pulmonary hypertension and chronic heart failure combined with Group 2 pulmonary hypertension are poised to launch.
Accelerating the Formation of an Overseas Expansion System, Striving to Become a Global Setter of Medical Standards
From Product Export to Systemic Globalization: Pulnovo Medical is Building a Global Development Pathway that is “Verifiable, Sustainable, and Aligned with International Standards.” In China, its PADN product has achieved commercialization first; overseas, leveraging the dual engines of the FDA Breakthrough Device designation and EU MDR certification, Pulnovo Medical is establishing an ecosystem for exporting original technologies through the synergistic development of clinical registration, regulatory pathways, and academic platforms. This financing round will provide significant support for Pulnovo Medical’s strategy of “technology internationalization plus pathway standardization,” further solidifying its strategic position as a Chinese-origin medical technology platform integrating into the global healthcare system.
EQT Capital Executive DirectorZoe Zhu stated“Pulnovo Medical, as an innovation pioneer in China’s medical device sector, combines originality with clinically verifiable evidence in its core PADN technology and possesses the capability to systematically advance global regulatory registrations and standardization pathways. In the fields of pulmonary hypertension and heart failure—areas that remain insufficiently addressed globally—Pulnovo Medical has provided a clear prototype of a solution. We are highly optimistic about the global expansion potential of PADN products and believe it is both a privilege and an honor to support Pulnovo Medical in continuing to lead technological innovation in pulmonary hypertension and heart failure, bringing new therapeutic hope to patients worldwide.”
Chairman and Executive Chairman of Pulnovo MedicalCynthia Chen stated:“We extend our gratitude to EQT and Qiming Venture Partners for their steadfast commitment to partnering with Pulnovo Medical, despite the heightened uncertainty in the global macroeconomic environment. Since its inception, Pulnovo Medical has remained dedicated to addressing genuine, unmet clinical needs by starting from the frontline of medical practice, and has continuously refined original, verifiable, and scalable technological solutions. We are well aware that establishing Chinese original technologies as international standards remains a challenging and arduous journey. Nevertheless, we are confident and motivated to continue prioritizing clinical value, delivering source-innovative technologies to patients worldwide, and enhancing their well-being.”